{
    "clinical_study": {
        "@rank": "31905", 
        "acronym": "EN", 
        "arm_group": [
            {
                "arm_group_label": "enteral nutrition", 
                "arm_group_type": "Experimental", 
                "description": "The patients receive treatment of enteral nutrition only."
            }, 
            {
                "arm_group_label": "Corticosteroid", 
                "arm_group_type": "Experimental", 
                "description": "The patients receive treatment of corticosteroid only."
            }, 
            {
                "arm_group_label": "Healthy control", 
                "arm_group_type": "No Intervention", 
                "description": "healthy people applied with normal diet."
            }
        ], 
        "brief_summary": {
            "textblock": "The pathogenesis of Crohn Disease (CD) is unknown, but there is evidence show that the\n      inadequate immune response or overreaction of the immune system against food antigens or\n      components of the commensal flora involve it. Corticosteroid therapy is effective for adult\n      patients with CD, but it has side effects and can't promote mucosal healing. In recent\n      years, Enteral nutrition (EN) is becoming primary therapy in induction and maintenance\n      remission of CD, especially in children. But the mechanism of EN in induction and\n      maintenance remission of CD is still unclear, and parts of patient have good clinical\n      response to EN therapy while other don't. So we design the study to explore whether EN\n      treats CD by effecting intestinal flora and whether the intestinal flora of patient with CD\n      relates with clinical response."
        }, 
        "brief_title": "Effects of Enteral Nutrition and Corticosteroid on Intestinal Flora in Induction Remission of Crohn Disease in Adult", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Crohn Disease", 
        "condition_browse": {
            "mesh_term": "Crohn Disease"
        }, 
        "detailed_description": {
            "textblock": "The pathogenesis of CD is unknown, but there is evidence show that the inadequate immune\n      response or overreaction of the immune system against food antigens or components of the\n      commensal flora involve it. Corticosteroid therapy is effective for adult patients with CD,\n      but it has side effects and can't promote mucosal healing. In recent years, EN is becoming\n      primary therapy in induction and maintenance remission of CD, especially in children. But\n      the mechanism of EN in induction and maintenance remission of CD is still unclear, and parts\n      of patient have good clinical response to EN therapy while other don't. So we design the\n      study to explore whether EN treats CD by effecting intestinal flora and whether the\n      intestinal flora of patient with CD relates with clinical response."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients should be in the age range of 18 - 75 years;\n\n          2. Patients should have clinical, imaging, endoscopic and histological diagnosis of CD\n             based on WHO criteria\n\n          3. Patients should have a CDAI score of more than 150 and have a CRP level of more than\n             10mg/L at enrollment;\n\n          4. Patients will not be excluded if they have received 5-ASA(Aminosalicylic acid) or\n             immunomodulator for >8 weeks and the dose is stable\n\n          5. Informed consent\n\n        Exclusion Criteria:\n\n          1. Patients who can't tolerate enteral nutrition because of complications, such as\n             complete intestinal obstruction, gastrointestinal perforation or bleeding etc.\n\n          2. Patients who receive corticosteroids or enteral nutrition or prebiotics\n             /probiotics/synbiotics/antibiotic treatment in the previous 4 weeks.\n\n          3. Patients who accompanied extra-intestinal manifestations, serve complications, and\n             active perianal disease and need other drug therapies.\n\n          4. Patients who had ostomy or colectomy or subtotal colectomy\n\n          5. Patients with end-stage disease or is expected likely to die during the study\n\n          6. Patients are participating in other clinical trials or participated within 6 months\n             prior to this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02056418", 
            "org_study_id": "ECDB-1"
        }, 
        "intervention": [
            {
                "arm_group_label": "enteral nutrition", 
                "description": "enteral nutrition only (Nutrison Fibre, 20-30kcal/kg/day)", 
                "intervention_name": "enteral nutrition", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Corticosteroid", 
                "description": "corticosteroid(equal dose to prednisone 0.75mg/kg/day,4 weeks)", 
                "intervention_name": "corticosteroid", 
                "intervention_type": "Drug", 
                "other_name": [
                    "prednisone", 
                    "hydrocortisone"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Hydrocortisone", 
                "Prednisone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nanjing", 
                    "country": "China", 
                    "state": "Jiangsu", 
                    "zip": "210002"
                }, 
                "name": "Department of General Surgery, Jinling hosptal,Medical School of Nanjing University"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Controlled, Single-blind Study of Effects of Enteral Nutrition and Corticosteroid on Intestinal Flora in Induction Remission of Crohn Disease in Adult", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change from baseline in diversity and composition of intestinal flora of stool every week and time point of clinical remission after intervention", 
            "measure": "change of intestinal flora of stool", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02056418"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Jinling Hospital, China", 
            "investigator_full_name": "Zhu Weiming", 
            "investigator_title": "professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Change from baseline of hematological and biochemical indexes (CRP(C-reactive protein), PCT(procalcitonin), ESR(erythrocyte sedimentation rate), Alb) of blood every week", 
                "measure": "biochemical indexes", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Change from baseline of CDAI every week", 
                "measure": "CDAI(Crohn's disease activity index)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Change from Baseline in Fecal Calcium Protein in every week", 
                "measure": "Fecal Calcium Protein", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }
        ], 
        "source": "Jinling Hospital, China", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jinling Hospital, China", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}